Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 May;53(5):331-3.
doi: 10.1136/ard.53.5.331.

Long term treatment of polymyalgia rheumatica with deflazacort

M A Cimmino  1 , G Moggiana, C Montecucco, R Caporali, S Accardo
Affiliations

Long term treatment of polymyalgia rheumatica with deflazacort

M A Cimmino et al. Ann Rheum Dis. 1994 May.

Abstract

Objectives: To evaluate the long term efficacy and tolerability of deflazacort, a corticosteroid reputed to have only minor side effects, in the treatment of polymyalgia rheumatica (PMR).

Methods: In a prospective open study, deflazacort was administered at an average initial dose of 21.8 mg/day for a mean period of 19 months in 40 patients with PMR.

Results: A highly significant improvement of clinical and laboratory parameters occurred one month after therapy onset. This improvement persisted for the whole study period. Laboratory parameters of tolerability did not change during the study. Mild to moderate steroid-related side effects occurred in 57.9% of the patients.

Conclusions: Deflazacort is effective in the treatment of PMR. Its long term safety profile may be superior to that of other corticosteroids.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ann Rheum Dis. 1981 Feb;40(1):1-5 - PubMed
    1. Ann Intern Med. 1982 Nov;97(5):672-80 - PubMed
    1. Ann Rheum Dis. 1983 Aug;42(4):374-8 - PubMed
    1. Am J Med. 1985 Sep;79(3):309-15 - PubMed
    1. Arch Intern Med. 1987 Apr;147(4):679-80 - PubMed